Completed PHASE3 INTERVENTIONAL 3-arm NCT02770157

Efficacy and Safety of DA-3002 in Short Children Borns SGA. (SGA)

Phase III Clinical Trial for Assessment of Efficacy and Safety of DA-3002 (Recombinant Human Growth Hormone) in Short Children Born Small for Gestational Age.

Sponsor: Dong-A ST Co., Ltd.

Conditions Infant, Small for Gestational Age

Interventions DA-3002 Genotropin®

Updated 8 times since 2017 Last updated: Oct 13, 2019 Started: Feb 26, 2016 Primary completion: Aug 28, 2019 Completion: Aug 28, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02770157, this PHASE3 trial focuses on Infant, Small for Gestational Age and remains completed. Sponsored by Dong-A ST Co., Ltd., it has been updated 8 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Nov 2019 — Jan 2021 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed

▶ Show 3 earlier versions

Sep 2018 — Nov 2019 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE3
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE3

First recorded

Feb 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dong-A ST Co., Ltd.

Data source: Dong-A ST Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea